Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05079113 · ClinicalTrials.gov registry record
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
A clinical trial of Stage III Melanoma and Stage IV Cutaneous Melanoma, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 73
- Enrollment target
- 1
- Study location
NCT05079113: Completed study of Stage III Melanoma and Stage IV Cutaneous Melanoma, sponsored by Case Comprehensive Cancer Center.
NCT05079113 is a study of Stage III Melanoma and Stage IV Cutaneous Melanoma that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 73 participants, above the 44-participant average among 5 other Stage III Melanoma trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05079113, a study of Stage III Melanoma and Stage IV Cutaneous Melanoma, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
Primary Outcome
Genomic sequencing of 40+ ctDNA genes will be analyzed to identify genetic alterations correlating with the development of recurrence in melanoma.
Conditions Studied
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2023-04-04 |
What the finished NCT05079113 record still lists
NCT05079113 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target, above the 44-participant average among 5 other Stage III Melanoma trials with a reported enrollment target (66% higher).
The record links to 2 conditions, with Stage III Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT05079113 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05079113 about?
NCT05079113 is a clinical study titled "Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting". To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
What is the current status of trial NCT05079113?
This trial is currently completed. The enrollment target is 73 participants. The study started on 2019-10-01. Estimated completion is 2023-04-04.
What conditions does trial NCT05079113 study?
This clinical trial studies the following conditions: Stage III Melanoma, Stage IV Cutaneous Melanoma.
Who is sponsoring clinical trial NCT05079113?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05079113 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
COMPLETED · Phase 1
-
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI